 |
|
Coffee and tea can reduce the risk of chronic liver disease
December 02, 2005A study published today in the American Gastroenterological Association (AGA) journal Gastroenterology found that people at high risk for liver injury may be able to reduce their risk for developing chronic liver disease significantly by drinking more than two cups of coffee or tea daily. This preventative effect was only seen in people at higher risk for liver disease due to heavy alcohol intake, being overweight or having diabetes or iron overload. This is the first study to take a prospective look at the relationship between coffee and tea consumption and chronic liver disease in the general U.S. population.
"While it is too soon to encourage patients to increase their coffee and tea intake, the findings of our study potentially offer people at high-risk for developing chronic liver disease a practical way to decrease that risk," said Constance E. Ruhl, MD, PhD, who conducted the study with colleague, James E. Everhart, MD, MPH. "In addition, we hope the findings will offer guidance to researchers who are studying liver disease progression."
Chronic liver disease is an ongoing injury to the cells of the liver, resulting in inflammation that lasts longer than six months. Its causes are numerous, including viruses, obesity, alcohol, metabolic or immunologic abnormalities, and side effects from various medications. Chronic liver diseases include cirrhosis, fibrosis and hepatitis. According to the most recent estimates from the National Center for Health Statistics, nearly 28,000 people die of chronic liver disease each year and there are more than 5 million prevalent cases of chronic liver disease and cirrhosis in the United States.
Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases and Social & Scientific Systems, Inc. conducted an analysis of patients using the first National Health and Nutrition Examination Survey (NHANES I) and the NHANES I Epidemiologic Follow-Up Study. The study population included 9,849 participants whose coffee and tea intake was evaluated and who were followed for a median of 19 years. In this analysis, coffee and tea intake was measured in cups, ranging from 0 to 16 cups per day with a median of two cups per day. Findings showed that those who consumed more than two cups of coffee or tea per day developed chronic liver disease at half the rate of those who drank less than one cup each day.
Over the last few years, there has been a growing body of evidence that coffee decreases the risk of elevated liver enzymes, cirrhosis and liver cancer. This study provides support for a protective effect of coffee on chronic liver disease and cirrhosis, and extends these findings to the general U.S. population. However, the study does not provide evidence that coffee and tea protect against chronic liver disease from individual causes, such as fatty liver disease or viral hepatitis.
"In the analysis, we determined that caffeine was partly responsible for the protective effect found. We believe that investigations into the mechanism of action of caffeine for protecting the liver and its clinical application are needed," said Dr. Ruhl.
American Gastroenterological Association
Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases and Social & Scientific Systems, Inc. conducted an analysis of patients using the first National Health and Nutrition Examination Survey (NHANES I) and the NHANES I Epidemiologic Follow-Up Study. The study population included 9,849 participants whose coffee and tea intake was evaluated and who were followed for a median of 19 years. In this analysis, coffee and tea intake was measured in cups, ranging from 0 to 16 cups per day with a median of two cups per day. Findings showed that those who consumed more than two cups of coffee or tea per day developed chronic liver disease at half the rate of those who drank less than one cup each day.
Over the last few years, there has been a growing body of evidence that coffee decreases the risk of elevated liver enzymes, cirrhosis and liver cancer. This study provides support for a protective effect of coffee on chronic liver disease and cirrhosis, and extends these findings to the general U.S. population. However, the study does not provide evidence that coffee and tea protect against chronic liver disease from individual causes, such as fatty liver disease or viral hepatitis.
"In the analysis, we determined that caffeine was partly responsible for the protective effect found. We believe that investigations into the mechanism of action of caffeine for protecting the liver and its clinical application are needed," said Dr. Ruhl.
American Gastroenterological Association
Chronic Liver Disease Current Events and Chronic Liver Disease News RSSUCSD researchers pave the way for effective liver treatments
A combination of bioengineering and medical research at the University of California, San Diego has led to a new discovery that could pave the way for more effective treatments for liver disease.
Probe position may change results in liver stiffness measurements in transient elastography
A major clinical challenge is to find the best method to evaluate and to manage the increasing numbers of patients with chronic liver disease. Liver biopsy, due to its risks and limitations, is no longer considered mandatory as the first-line indicator of liver injury, and several markers have been developed as non-invasive alternatives.
NEJM Study Points to New Era in Hepatitis C Treatment
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Liver disease 'shrunk' by blood-pressure drug
A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients.
Hyperferritinemia is another surrogate marker of advanced liver disease
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients.
Diabetes, obesity and hypertension increase mortality in hepatitis C patients
The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.
A rigorous method for liver biopsy
Liver biopsy is still considered the gold standard for grading, staging and "stad-ging" the chronic liver disease. In addition, it remains a primary source for acquiring new knowledge on the liver pathology.
Hepatitis C Treatment Reduces the Virus but Liver Damage Continues
Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.
Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.
If the diabetes has a direct carcinogenetic effect?
The association of DM2 with solid tumors, and particularly with HCC, has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2.
More Chronic Liver Disease Current Events and Chronic Liver Disease News Articles
 |
The Comfort of Home for Chronic Liver Disease: A Guide for Caregivers by Lucy Mathew NP (Author), Jill Chang (Author), Maria M. Meyer (Author), RN Paula Derr (Author) Despite the growing number of hepatitis B and C and liver cancer patients in the United States, knowledge of liver disease is limited even among health care professionals. A caregiver that knows more about this complex affliction can greatly increase a patient's ability to cope. This disease-specific guide aims to educate and instruct both professional home-health aides and family caregivers, in order to ensure the patient's quality of life and comfort and help caregivers through challenging courses of treatment. |
 |
The Future of Hepatitis C Directed By: ITV Also With: ITV (Producer) |
 |
Parsley Root - For chronic liver and gallbladder diseases, water retention, kidney congestion, 2 oz., (Health Herb) by HerbalLoveShop Parsley is a diuretic, blood purifier, carminative, and hepatic. PARSLEY ROOT (Petroselinum sativum) Useful for chronic liver and gallbladder diseases. The roots act most readily on the kidneys in comparison to other parts of the plant. Combine Parsley Root with Plantain and Marshmallow Root for kidney and bladder infections. It is strengthening for weak and sensitive people simply by adding a couple slices fo the root to a soup. Other indications: difficult urination, dropsy, jaundice, all stones, liver and spleen obstructions, asthma, water retention, coughs, kidney congestion, tumors, female problems, and after-pains of birth. CAUTION: Do not use if inflammation of the kidneys is present. For chronic liver and gallbladder diseases, water retention, kidney congestion. |
 |
Balanceuticals Stomach Fortifier Dietary Supplement Capsules, 500 mg, 60-Count Bottles (Pack of 2) by Balanceuticals Dietary supplement. 100% Natural. Made under supervision by China Academy of Traditional Chinese Medicine. This well-known formula is made of ginseng root, poria (Indian bread), attractylodes, common yam, hyacinth bean, coix, ammonium seed, platcodon and licorice. Chinese medicine uses it to strengthen the spleen and stomach, normalize peristalsis of the stomach and intestines, promote absorption of water and chlorine ion, improve metabolism, nurture the lung, balance bowel movements and increase energy. (This statement has not been evaluated by the FDA. This produc is not intended to diagnose, treat, cure of prevent any disease.) |
|
Surrogate Markers to Assess Efficacy of Treatment in Chronic Liver Diseases (Falk Symposium) by J. Reichen (Editor), Raoul E. Poupon (Editor) Recent years have seen an increasing number of supposedly active drugs for the treatment of chronic liver diseases, e.g. ursodeoxycholate for treatment of cholestatic conditions and alpha-interferon for the treatment of chronic viral hepatitis. However, in all controlled studies, hard end-points such as survival or need for transplantation often cannot be obtained, owing to the prolonged course of chronic liver diseases up to the time of hepatic decompensation and death. Therefore, surrogate markers for the different conditions are sorely needed in order to assess the value of these novel treatment modalities. This book, the proceedings of an International Falk Workshop held in Basel, Switzerland, October 23--24, 1995, aims to define surrogate markers and to evaluate... | |
 |
Metabolic Aspects of Chronic Liver Disease by Ami Schattner (Editor) This book discusses in detail new aspects of the metabolic basis of important chronic liver diseases. Entities such as non-alcoholic fatty liver disease (fatty liver and Non-Alcoholic SteatoHepatitis - NASH), diabetes in chronic hepatitis C, hemochromatosis, Wilson's disease, Gaucher disease, porphyria, as well as liver cirrhosis and its metabolic consequences will be discussed in detail. These clinical conditions are highly prevalent and affect millions of patients in the USA and world-wide. For example, non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes in the general population. This field has been practically transformed over the last few years, with many new insights gained, regarding both pathogenesis and effective novel treatments. |
|
Silence Is Deadly Directed By: Kindra Ruocco | |
|
Chronic disease reports: deaths from chronic liver disease - United States, 1986.: An article from: Morbidity and Mortality Weekly Report by U.S. Government Printing Office (Publisher) This digital document is an article from Morbidity and Mortality Weekly Report, published by U.S. Government Printing Office on November 24, 1989. The length of the article is 803 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Chronic disease reports: deaths from chronic liver disease - United States, 1986. Publication: Morbidity and Mortality Weekly Report (Newsletter) Date: November 24, 1989 Publisher: U.S. Government Printing Office Volume: v38 Issue: n46 Page: p792(4) Distributed by Thomson... | |
|
Chronic Liver Disease (Frontiers of Gastrointestinal Research) by M. U. Dianzani (Author), P. Gentilini (Editor) | |
 |
Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle by Balanceuticals Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. |
| © 2009 BrightSurf.com |